Sunovion is presenting results from a 26-week double-blind, randomized Phase 3 study of ciclesonide HFA nasal aerosol involving more than 1,100 patients with perennial allergic rhinitis (PAR) that showed statistically significant improvement in nasal symptoms for ciclesonide compared to placebo. The study demonstrated positive results for both a 74 mcg dose and a 148 … [Read more...] about Positive Phase 3 results for ciclesonide nasal aerosol for perennial allergic rhinitis
Medical
Lightlake provides additional details on studies of nasal spray for eating disorders
Lightlake Therapeutics has provided additional details of recently announced Phase 2 trials of its naloxone nasal spray for binge eating disorder and for bulimia nervosa. Binge eating disorder trials have begun in Helsinki, with 138 patients randomly selected from more than 900 applicants taking either intranasal naloxone or a placebo nasal spray, says the … [Read more...] about Lightlake provides additional details on studies of nasal spray for eating disorders
Phase 3 results for Merck’s Dulera for the treatment of COPD
Merck has announced results of two Phase 3 clinical studies of Dulera mometasone furoate/formoterol fumarate inhalation aerosol for the treatment of COPD that show statistically significant improvement in lung function in most of the combinations studied and document the incidence of treatment-related adverse events for two dosage strengths. Dulera is approved in the … [Read more...] about Phase 3 results for Merck’s Dulera for the treatment of COPD
Insight recalls lot of Nostrilla nasal decongestant spray
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092 1/2-oz bottles, was distributed in US retail stores and pharmacies. According to Insight, it has … [Read more...] about Insight recalls lot of Nostrilla nasal decongestant spray
Some acetylcysteine inhalation solution now available
According to the FDA, American Regent/Luitpold has now released several batches of acetylcysteine inhalation solution, including 10 ml vials of both 100 mg/ml and 200 mg/ml solutions and 30 ml vials of the 200 mg/ml solution. The company's facility in Shirley, NY was closed in April 2011 due to safety concerns. Two other manufacturers, Roxanne Laboratories and … [Read more...] about Some acetylcysteine inhalation solution now available
Acton publishes positive Phase 3b data for flunisolide inhaler
Acton Pharmaceuticals has published positive results from a Phase 3b clinical trial of its Aerospan flunisolide HFA metered dose inhaler in the October issue of Annals of Allergy, Asthma & Immunology. The article, titled, "Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled hydrofluoroalkane in prepubescent children with mild persistent … [Read more...] about Acton publishes positive Phase 3b data for flunisolide inhaler
Trimel concludes Phase 2 study of intranasal gel for female sexual dysfunction
Trimel Pharmaceuticals plans to present data from a recently completed Phase 2 "vibro-tactile stimulation (VTS) study" of its TBS-2 intranasal gel for the treatment of anorgasmia in women to the FDA at a meeting scheduled for November 2011. According to Trimel, in August 2011, it notified the CRO conducting the study that "patient enrolment would be considered … [Read more...] about Trimel concludes Phase 2 study of intranasal gel for female sexual dysfunction
Teva UK launches generic HFA salmeterol MDI
Teva UK has announced the launch of a generic CFC-free salmeterol metered dose inhaler in the UK; the product is a suspension pMDI that delivers 25 mcg per actuation. The UK granted marketing authorization for the Neovent/Sereflo inhaler for the treatment of asthma and COPD to Neolab Limited in April 2011. Kim Innes, Teva UK Commercial Director, commented, "We are … [Read more...] about Teva UK launches generic HFA salmeterol MDI
Lightlake announces Phase 2 trial of nasal spray for bulimia nervosa
King's College London will be the site of Phase 2 trials of Lightlake Therapeutics's opioid antagonist-based nasal spray treatment for bulimia nervosa, the company has announced. Lightlake currently has Phase 2 trials underway in Finland to demonstrate the effectiveness of its naloxone nasal spray for the treatment of binge eating disorder in overweight and obese … [Read more...] about Lightlake announces Phase 2 trial of nasal spray for bulimia nervosa
Quebec is first Canadian province to offer formulary access to TOBI Podhaler
Novartis Pharmaceuticals Canada has announced that the Québec provincial government will now provide reimbursement for the TOBI Podhaler tobramycin DPI for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.The company cites data from Cystic Fibrosis Canada that show about 1,200 cystic fibrosis patients residing in Québec. TOBI Podhaler … [Read more...] about Quebec is first Canadian province to offer formulary access to TOBI Podhaler